SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics

Parexel releases report on advancing precision oncology

Parexel, one of the world’s largest clinical research organizations providing the full range of phase I to IV clinical development services, has released a new report in their expert series, New Medicines, Novel Insights.

May 24, 2024

Vol.50 No.21

Clinical Trials & Tribulations

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.

May 10, 2024

Vol.50 No.19

By Sanju Sinha and Eytan Ruppin

In Brief

Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

The Northwell Health Cancer Institute and its Center for Genomic Medicine opened Long Island’s first clinical Molecular Diagnostics Laboratory, a $3.2 million 2,800 square foot state-of-the-art facility with technology of next-generation sequencing that provides point-of-care tumor and patient genomic profiling to inform precision cancer therapy.

May 10, 2024

Vol.50 No.19

In Brief

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Drugs & Targets

Tempus contributes de-identified cancer data to NCI’s planned data enclave

Tempus has sent de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the NCI.

March 22, 2024

Vol.50 No.12

SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics

YOU MAY BE INTERESTED IN

Parexel releases report on advancing precision oncology

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Tempus contributes de-identified cancer data to NCI’s planned data enclave

Renew today!

Subscriber content

Login